PTPN11 and colorectal cancer: It was found that SHP2 deneddylation, through the CD47/SIRPα axis, mediated tumor immune suppression in colon cancer, and the administration of allosteric SHP2 inhibitors sensitized immunotherapy-resistant colorectal cancer to immunotherapy 157.